Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzoates
  • Neoplasms
  • Receptors, Leukotriene B4

abstract

  • LY293111 can be administered safely by continuous oral therapy with mild toxicities. Diarrhea is dose-limiting. The recommended phase II dose will be 600 mg BID. The steady-state concentrations in humans exceed relevant levels observed in preclinical models.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.02.766

PubMed ID

  • 15939925

Additional Document Info

start page

  • 5365

end page

  • 73

volume

  • 23

number

  • 23